Loading...
Botanix Pharmaceuticals Limited
BOT.AX•ASX
Healthcare
Biotechnology
A$0.14
A$-0.01(-3.33%)
Botanix Pharmaceuticals Limited (BOT.AX) Financial Performance & Income Statement Overview
Review Botanix Pharmaceuticals Limited’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-34.23%
↓ 34.23%
Operating Income Growth
-20.82%
↓ 20.82%
Net Income Growth
-51.52%
↓ 51.52%
Operating Cash Flow Growth
32.69%
↑ 32.69%
Operating Margin
-1924.58%
↓ 1924.58%
Gross Margin
-87.64%
↓ 87.64%
Net Profit Margin
-1898.88%
↓ 1898.88%
ROE
-39.05%
↓ 39.05%
ROIC
-42.79%
↓ 42.79%
Botanix Pharmaceuticals Limited (BOT.AX) Income Statement & Financial Overview
Review Botanix Pharmaceuticals Limited's (BOT.AX) income statement with detailed quarterly and annual figures.
| Metric | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $377597.00 | $1.69M | $377930.00 | $526976.00 |
| Cost of Revenue | $1.21M | $2.67M | $3.40M | $2.71M |
| Gross Profit | -$831000.00 | -$982000.00 | -$3.02M | -$2.19M |
| Gross Profit Ratio | -$2.20 | -$0.58 | -$8.004 | -$4.15 |
| R&D Expenses | $138077.00 | $834730.00 | $978208.00 | $636670.00 |
| SG&A Expenses | $30.02M | $2.80M | $1.52M | $1.69M |
| Operating Expenses | $30.16M | $7.85M | $2.50M | $2.33M |
| Total Costs & Expenses | $31.37M | $10.52M | $5.90M | $5.04M |
| Interest Income | $0.00 | $34162.00 | $41559.00 | $46946.00 |
| Interest Expense | $0.00 | $4032.00 | $6627.00 | $5064.00 |
| Depreciation & Amortization | $1.12M | $64176.00 | $8431.00 | $93606.00 |
| EBITDA | -$30.85M | -$8.40M | -$5.52M | -$4.46M |
| EBITDA Ratio | -$81.71 | -$4.97 | -$14.60 | -$8.39 |
| Operating Income | -$30.99M | -$8.83M | -$5.53M | -$4.51M |
| Operating Income Ratio | -$82.07 | -$5.22 | -$14.62 | -$8.57 |
| Other Income/Expenses (Net) | $103338.00 | -$1.04M | $59146.00 | -$42679.00 |
| Income Before Tax | -$30.92M | -$9.87M | -$5.47M | -$4.56M |
| Income Before Tax Ratio | -$81.89 | -$5.83 | -$14.47 | -$8.65 |
| Income Tax Expense | -$31924.00 | -$1.47M | $0.00 | $4.00 |
| Net Income | -$30.89M | -$8.40M | -$5.47M | -$4.56M |
| Net Income Ratio | -$81.80 | -$4.97 | -$14.47 | -$8.65 |
| EPS | -$0.02 | -$0.005 | -$0.004 | -$0.004 |
| Diluted EPS | -$0.02 | -$0.005 | -$0.004 | -$0.004 |
| Weighted Avg Shares Outstanding | $1.82B | $1.56B | $1.44B | $1.31B |
| Weighted Avg Shares Outstanding (Diluted) | $1.82B | $1.56B | $1.44B | $1.31B |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan